Telix Pharmaceuticals Limited (NASDAQ:TLX – Get Free Report) shares were up 8.7% during trading on Thursday . The stock traded as high as $9.43 and last traded at $9.5350. Approximately 77,501 shares changed hands during mid-day trading, a decline of 64% from the average daily volume of 212,775 shares. The stock had previously closed at $8.77.
Analysts Set New Price Targets
Several equities research analysts recently commented on TLX shares. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Monday, April 13th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Monday, April 20th. Wedbush reaffirmed an “outperform” rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Monday, April 13th. Wall Street Zen raised shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. Finally, Citigroup boosted their price objective on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the company a “buy” rating in a research report on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Telix Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $21.13.
Get Our Latest Stock Analysis on Telix Pharmaceuticals
Telix Pharmaceuticals Stock Up 8.4%
Insiders Place Their Bets
In other Telix Pharmaceuticals news, CEO Christian Behrenbruch bought 34,500 shares of the firm’s stock in a transaction that occurred on Tuesday, April 28th. The stock was acquired at an average price of $14.48 per share, with a total value of $499,560.00. Following the completion of the transaction, the chief executive officer owned 20,709,500 shares in the company, valued at approximately $299,873,560. This trade represents a 0.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Institutional Trading of Telix Pharmaceuticals
A number of large investors have recently added to or reduced their stakes in TLX. Rhumbline Advisers increased its stake in shares of Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after purchasing an additional 1,392 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after purchasing an additional 8,423 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Telix Pharmaceuticals during the 4th quarter worth about $89,000. XY Capital Ltd acquired a new position in shares of Telix Pharmaceuticals during the 1st quarter worth about $120,000. Finally, IHT Wealth Management LLC acquired a new position in shares of Telix Pharmaceuticals during the 2nd quarter worth about $213,000.
Telix Pharmaceuticals Company Profile
Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.
The company’s pipeline spans both imaging and therapeutic candidates.
Featured Stories
- Five stocks we like better than Telix Pharmaceuticals
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
- Rocket Lab Is Down 24% From Its 52-Week High—Pullback or Problem?
- The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker
- Before the IPO: 4 Companies That Rewarded Investors Who Got In Early
Receive News & Ratings for Telix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
